Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Georges Vauquelin

Showing results (1-10 of 78) with videos related to

Pageof 8
Sort By:
British Journal of Clinical Pharmacology|May 3, 2016
Cell membranes… and how long drugs may exert beneficial pharmacological activity in vivoGeorges Vauquelin
Naunyn-Schmiedeberg'S Archives of Pharmacology|July 2, 2013
Simplified models for heterobivalent ligand binding: when are they applicable and which are the factors that affect their target residence timeGeorges Vauquelin
British Journal of Pharmacology|April 30, 2016
Effects of target binding kinetics on in vivo drug efficacy: koff , kon and rebindingGeorges Vauquelin
Expert Opinion on Drug Discovery|July 14, 2015
On the 'micro'-pharmacodynamic and pharmacokinetic mechanisms that contribute to long-lasting drug actionGeorges Vauquelin
British Journal of Pharmacology|August 25, 2017
Distinct in vivo target occupancy by bivalent- and induced-fit-like binding drugsGeorges Vauquelin
Medchemcomm|October 6, 2018
Link between a high <i>k</i> <sub>on</sub> for drug binding and a fast clinical action: to be or not to be?Georges Vauquelin
Expert Opinion on Drug Discovery|July 25, 2012
Rebinding: or why drugs may act longer in vivo than expected from their in vitro target residence timeGeorges Vauquelin
Pharmacology Research & Perspectives|August 30, 2021
Induced fit versus conformational selection: From rate constants to fluxes… and back to rate constantsGeorges Vauquelin, Dominique Maes
Neurochemistry International|July 4, 2007
Kinetic versus allosteric mechanisms to explain insurmountable antagonism and delayed ligand dissociationGeorges Vauquelin, Anna Szczuka
Fundamental & Clinical Pharmacology|August 18, 2022
Competition in drug binding and … the race to equilibriumGeorges Vauquelin, Dominique Maes
Pageof 8

Showing results (1-10 of 78) with videos related to

Sort By:
Pageof 8
British Journal of Clinical Pharmacology|May 3, 2016
Cell membranes… and how long drugs may exert beneficial pharmacological activity in vivoGeorges Vauquelin
Naunyn-Schmiedeberg'S Archives of Pharmacology|July 2, 2013
Simplified models for heterobivalent ligand binding: when are they applicable and which are the factors that affect their target residence timeGeorges Vauquelin
British Journal of Pharmacology|April 30, 2016
Effects of target binding kinetics on in vivo drug efficacy: koff , kon and rebindingGeorges Vauquelin
Expert Opinion on Drug Discovery|July 14, 2015
On the 'micro'-pharmacodynamic and pharmacokinetic mechanisms that contribute to long-lasting drug actionGeorges Vauquelin
British Journal of Pharmacology|August 25, 2017
Distinct in vivo target occupancy by bivalent- and induced-fit-like binding drugsGeorges Vauquelin
Medchemcomm|October 6, 2018
Link between a high <i>k</i> <sub>on</sub> for drug binding and a fast clinical action: to be or not to be?Georges Vauquelin
Expert Opinion on Drug Discovery|July 25, 2012
Rebinding: or why drugs may act longer in vivo than expected from their in vitro target residence timeGeorges Vauquelin
Pharmacology Research & Perspectives|August 30, 2021
Induced fit versus conformational selection: From rate constants to fluxes… and back to rate constantsGeorges Vauquelin, Dominique Maes
Neurochemistry International|July 4, 2007
Kinetic versus allosteric mechanisms to explain insurmountable antagonism and delayed ligand dissociationGeorges Vauquelin, Anna Szczuka
Fundamental & Clinical Pharmacology|August 18, 2022
Competition in drug binding and … the race to equilibriumGeorges Vauquelin, Dominique Maes
Pageof 8